Status:
COMPLETED
Acupuncture for Aromatase Inhibitor Induced Joint Pain
Lead Sponsor:
Columbia University
Conditions:
Breast Cancer
Eligibility:
FEMALE
45+ years
Phase:
NA
Brief Summary
This is a randomized, controlled, pilot study to determine the safety and efficacy of acupuncture as an adjunct to pharmacological treatment compared to pharmacological intervention alone for the trea...
Detailed Description
The purpose of this study is to determine the safety and efficacy of acupuncture as a complementary therapy to pain medication for joint pain associated with aromatase inhibitors for breast cancer tre...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Age\>45 years
- Postmenopausal status defined as cessation of menses for \>1 year or follicle- stimulating hormone (FSH)\>20 mIU/mL
- History of stage I or II, hormone receptor-positive breast cancer
- Currently taking a third-generation aromatase inhibitor (anastrazole, letrozole or exemestane)
- Ongoing musculoskeletal pain in one or more joints (baseline BPI worst pain score \> 3 points on a scale of 0 to 10)
- English-speaking
- Signed informed consent
- EXCLUSION CRITERIA:
- Previous treatment with acupuncture
- Inflammatory, metabolic or neuropathic arthropathies
- Bone fracture or surgery of the afflicted extremity during the past six months
- Current narcotic use, corticosteroid therapy or cortisone injections
- Severe concomitant illnesses or metastatic disease
- Severe coagulopathy or bleeding disorder
- Dermatological disease within the acupuncture area
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00826397
Start Date
June 1 2005
End Date
September 1 2009
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University
New York, New York, United States, 10032